Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.

Iberdomide

  Cat. No.:  DC10174   Featured
Chemical Structure
1323403-33-3
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86 21 58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Iberdomide (CC-220) is a cereblon modulator currently undergoing clinical development for the treatment of systemic lupus erythematosus. It demonstrates potent activity with an IC50 of 60 nM in a TR-FRET cereblon binding assay.
Cas No.: 1323403-33-3
Chemical Name: Iberdomide
Synonyms: Iberdomide;CC 220;CC-220;CC220;8V66F27X44;(S)-3-(4-((4-(Morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;(3s)-3-[4-({4-[(Morpholin-4-Yl)methyl]phenyl}methoxy)-1-Oxo-1,3-Dihydro-2h-Isoindol-2-Yl]piperidine-2,6-Dione;Iberdomide [USAN];Iberdomide (USAN/INN);GTPL9618;BDBM65497;IXZOHGPZAQLIBH-NRFANRHFSA-N;BCP20299;compound 6 [PMID: 28425720];SB18830;DB12101;D111
SMILES: O(C([H])([H])C1C([H])=C([H])C(=C([H])C=1[H])C([H])([H])N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H])C1=C([H])C([H])=C([H])C2C(N(C([H])([H])C=21)[C@]1([H])C(N([H])C(C([H])([H])C1([H])[H])=O)=O)=O
Formula: C25H27N3O5
M.Wt: 449.4990
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: Iberdomide (CC-220) is a cereblon modulator with an IC50 of 60 nM.
In Vivo: Iberdomide (CC-220) is currently in phase 2 clinical trials for the treatment of systematic lupus erythematosus (SLE) and phase 1b/2a clinical trials for relapsed and refractory multiple myeloma (MM)[1].
In Vitro: Lenalidomide and pomalidomide, targeting cereblon, are immunomodulatory drugs that are clinically effective in the treatment of cancer, including newly diagnosed and relapsed multiple myeloma. Iberdomide contains a glutarimide ring that binds in the try-tryptophan pocket of cereblon and an isoindolinone ring that can interact with both cereblon and substrates. Treatment with Iberdomide results in the loss of Ikaros and Aiolos protein levels with EC50s of 1 nM and 0.5 nM [1].
X